PTH and Huntington disease: The key findings of this study were: 1.—Etelcalcetide proved to reduce PTH levels in HD patients with severe SHP; 2.—No significant adverse events were reported; 3.—The possibility of a synergic anti-inflammatory effect with the simultaneous IV uses of paricalcitol and etelcalcetide.